Equities
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,540.00
  • Today's Change-12.00 / -0.77%
  • Shares traded1.15m
  • 1 Year change-32.87%
  • Beta1.1634
Data delayed at least 20 minutes, as of Feb 06 2026 14:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Key statistics

On Friday, Hikma Pharmaceuticals PLC (HIK:LSE) closed at 1,540.00, 3.91% above its 52-week low of 1,482.00, set on Dec 15, 2025.
52-week range
Today
1,482.00Dec 15 20252,360.00Feb 13 2025
Short selling activity
Low
Med
High
Provided by S&P Global Market Intelligence
Open1,541.00
High1,569.00
Low1,511.00
Bid1,500.00
Offer1,803.00
Previous close1,552.00
Average volume1.21m
Shares outstanding221.89m
Free float153.35m
P/E (TTM)12.60
Market cap3.44bn GBP
EPS (TTM)1.23
GBP
Annual div (ADY)63.79
GBX
Annual div yield (ADY)4.11%
Div ex-dateAug 14 2025
Div pay-dateSep 18 2025
Data delayed at least 20 minutes, as of Feb 06 2026 14:55 GMT.
More ▼

Investors Chronicle View

The last IC recommendation on Hikma Pharmaceuticals PLC shares was Hold at 1,750.00 on 07 Aug 2025Read the full article

Board of Directors

1/11

Said Darwazah, Executive Chairman

2/11

Riad Mishlawi, Chief Executive Officer

3/11

Mazen Darwazah, Executive Vice Chairman, President of MENA

4/11

Victoria Hull, Nomination and Governance Committee Chairman, Senior Independent Non-Executive Director

5/11

Ali Al-Husry, Non-Executive Director

6/11

Nina Henderson, Independent Non-Executive Director

7/11

Cynthia Flowers, Remuneration Committee Chairman, Independent Non-Executive Director

8/11

Douglas Hurt, Audit Committee Chairman, Independent Non-Executive Director

9/11

Laura Balan, Designated Independent Non-Executive Director for Workforce Engagement

10/11

Deneen Vojta, CREC Chairman, Independent Non-Executive Director

11/11

Helen Middlemist, Group Company Secretary

Contact

Address:
Hikma Pharmaceuticals PLC
1 New Burlington Place
London
W1S 2HR

T: +44 (0) 20 7399 2760
F: +44 (0) 20 7399 2761
E: investors@hikma.uk.com
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.